Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1010.4 (Moderna Inc)
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
mRNA-1010.4 is an investigational quadrivalent mRNA-based vaccine candidate developed by Moderna for the prevention of seasonal influenza. It is a specific variation of the parent candidate mRNA-1010, designed to evaluate optimized formulations or dosages. The vaccine utilizes messenger RNA encapsulated within lipid nanoparticles (LNPs) to encode the hemagglutinin (HA) glycoproteins of four World Health Organization-recommended influenza strains: influenza A (H1N1 and H3N2) and influenza B (Yamagata and Victoria lineages). Upon administration, the mRNA is translated by the host's cellular machinery to produce the viral HA proteins, which then trigger an immune response, including the production of neutralizing antibodies and T-cell activation. mRNA-1010.4 is currently being evaluated in Phase 2 clinical trials to assess its safety, reactogenicity, and immunogenicity in healthy adults.
- Other names
- mRNA-1010 variation 4mRNA1010 variation 4mRNA 1010 variation 4
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on mRNA-1010.4 (Moderna Inc).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1010.4 (Moderna Inc).